Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 232 clinical trials
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

docetaxel
taxane
combined modality therapy
cancer
prostatic neoplasm
  • 0 views
  • 19 Feb, 2024
Comparison of Diuretic Effect With Furosemide Alone Versus the Combination of Furosemide and Albumin in Cirrhotic Patients

A common complication of the progression of cirrhosis is fluid retention (ascites, edema, or pleural effusion). Loop diuretics are the treatment of choice for fluid retention in cirrhotic patients; however, many of these patients demonstrate diuretic resistance, requiring higher doses of the diuretics to achieve adequate diuresis. The cause of …

furosemide
diuretics
cirrhosis
hypoalbuminemia
ascites
  • 0 views
  • 19 Feb, 2024
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.

  • 0 views
  • 19 Feb, 2024
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

The purpose of this phase I/Ib study is to determine the safety profile of NIZ985 (new formulation), and if it can be safely combined with Spartalizumab and to determine the appropriate dose and schedule for further study. Moreover, the study will characterize the pharmacokinetic profiles of NIZ985 as a single …

  • 0 views
  • 19 Feb, 2024
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.

peg-asparaginase
biological therapy
serum bilirubin
cancer
renal function
  • 0 views
  • 19 Feb, 2024
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.

azacitidine
chidamide
measurable disease
t-cell lymphoma
tucidinostat
  • 0 views
  • 19 Feb, 2024
Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

The prognosis of PTCL (except early stage ALK+ ALCL) is dismal. Previous study showed that single agent lenalidomide showed promising therapeutic activity in patients with relapsed or refractory PTCL. The investigators therefore design this phase II study to investigate the safety and efficacy of lenalidomide in combination with CHOP in …

anaplastic large cell lymphoma
peripheral t-cell lymphoma
lenalidomide
  • 0 views
  • 19 Feb, 2024
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Background Glioblastoma is a type of brain cancer. Treatments include radiation, chemotherapy, and surgery. But survival rates are poor. Researchers think that the drug selinexor, when combined with chemotherapy and radiation, might help. Objective To learn the highest dose of selinexor that people with brain cancer can tolerate when given …

neutrophil count
absolute neutrophil count
therapeutic agents
temozolomide
platelet count
  • 0 views
  • 19 Feb, 2024
Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC

This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of radical chemoradiotherapy plus oral capecitabine/teggio for 1 year in patients with N3.

nasopharyngeal biopsy
carcinoma
alt/ast
capecitabine
nasopharyngeal carcinoma
  • 0 views
  • 19 Feb, 2024
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

obinutuzumab
chronic lymphocytic leukemia
lymphoma
b-cell lymphoma refractory
contraceptive use
  • 0 views
  • 19 Feb, 2024